Revised SPC: Kaletra (ritonavir and lopinavir) 100mg/25mg and 200mg/50mg film-coated tablets and 80mg/20mg oral solution -

Revised SPC: Kaletra (ritonavir and lopinavir) 100mg/25mg and 200mg/50mg film-coated tablets and 80mg/20mg oral solution
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Infection and infectious diseases
Summary
Section 4.3 now includes contraindications for quetiapine and avanafil, a warning on the use of avanafil has been added to section 4.4, and section 4.5 has been updated to include drug interaction information on quetiapine and avanafil.
UKMi comment
The SPCs for Norvir (ritonavir) products have also been updated to advise of the quetiapine and avanafil contraindication; vardenafil is also now contraindicated (this is already included in the Kaletra SPCs).
Related links: